Video

Dr. Kluger on the Challenges of Treating Melanoma

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the changes and challenges of treating patients with melanoma.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the changes and challenges of treating patients with melanoma.

Kluger says things are changing in the field of melanoma treatment. Ten years ago, a newly-diagnosed metastatic patient would be told that the median survival is approximately 6-9 months. However, patients and physicians now do not talk about survival rates with newly diagnosed patients, Kluger say, because of new anti-PD-1 agents, like nivolumab and lambrolizumab (MK-3475).

A recent phase I trial of nivolumab has shown a median duration of response was almost 2 years and patients with metastatic melanoma can now work, exercise, and live their lives.

Though these agents can have extremely durable responses, there is currently no way of predicting who will respond and how long they will respond for, which makes treating the disease very challenging.

Related Videos
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA